Hudson Bay Capital Management
BTAI icon

Hudson Bay Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Hudson Bay Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,831
Closed -$195K – 814
2023
Q2 		$195K Buy
+1,831
New +$610K ﹤0.01% 658
2022
Q1 		– Sell
-625
Closed -$203K – 1205
2021
Q4 		$203K Sell
625
-1,563
-71% -$671K ﹤0.01% 904
2021
Q3 		$1.06M Sell
2,188
-312
-12% -$137K 0.01% 736
2021
Q2 		$1.16M Buy
+2,500
New +$1.36M 0.01% 709

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hudson Bay Capital Management's BTAI Position: Q3 2023 in Review

Hudson Bay Capital Management sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 1,831 shares — an estimated $195K sold.

Hudson Bay Capital Management first reported a position in BTAI in Q2 2021 and held it in 4 quarters. The position peaked at $1.16M in Q2 2021. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

  • Hudson Bay Capital Management reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,831 BioXcel Therapeutics shares in Q3 2023, an estimated $195K.
  • Hudson Bay Capital Management first reported a position in BioXcel Therapeutics in Q2 2021 and held it in 4 quarters.
  • Hudson Bay Capital Management's BioXcel Therapeutics position peaked at $1.16M in Q2 2021.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on Hudson Bay Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.